ArticleJournal of virology2001
Nef from human immunodeficiency virus type 1(F12) inhibits viral production and infectivity.
Article in Journal of virology, 2001. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 33 citations in OpenAlex.
- N-Terminal Fatty Acids of NEFVaccines · 2020Article
- IFITM proteins inhibit HIV-1 protein synthesis.Scientific reports · 2018Article
- A Truncated Nef Peptide from SIVcpz Inhibits the Production of HIV-1 Infectious Progeny.Viruses · 2016Article
- Crystal structure of an antiviral ankyrin targeting the HIV-1 capsid and molecular modeling of the ankyrin-capsid complex.Journal of computer-aided molecular design · 2014Article
- Cell activation and HIV-1 replication in unstimulated CD4+ T lymphocytes ingesting exosomes from cells expressing defective HIV-1.Retrovirology · 2014Article
- A mutant Tat protein provides strong protection from HIV-1 infection in human CD4+ T cells.Human gene therapy · 2013Article
- Cyclin K inhibits HIV-1 gene expression and replication by interfering with cyclin-dependent kinase 9 (CDK9)-cyclin T1 interaction in Nef-dependent manner.The Journal of biological chemistry · 2011Article
- Exogenous HIV-1 Nef upsets the IFN-γ-induced impairment of human intestinal epithelial integrity.PloS one · 2011Article
- Interactions between Nef and AIP1 proliferate multivesicular bodies and facilitate egress of HIV-1.Retrovirology · 2006Article
- Retroviral superinfection resistance.Retrovirology · 2005Review
- Replicative homeostasis: a fundamental mechanism mediating selective viral replication and escape mutation.Virology journal · 2005Article
- Nef binds p6* in GagPol during replication of human immunodeficiency virus type 1.Journal of virology · 2004Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 3 countries.
Funding
Abstract
Human immunodeficiency virus type 1(F12) (HIV-1(F12)) interferes with the replication of other strains of HIV. Its accessory protein, Nef, is sufficient for this phenotype, where the production and infectivity of HIV are impaired significantly. The analysis of three rare mutations in this Nef protein revealed that these effects could be separated genetically. Moreover, the defect in virus production correlated with the lack of processing of the p55(Gag) precursor in the presence of Nef from HIV-1(F12). Importantly, the introduction of one of these mutations (E177G) into Nef from HIV-1(NL4-3) also created a dominant-negative Nef protein. Effects of Nef from HIV-1(F12) on virus production and Gag processing correlated with its altered subcellular distribution. Moreover, the association with two new cellular proteins with molecular masses of 74 and 75 kDa, which do not interact with other Nef proteins, correlated with the decreased virion infectivity. The identification of a dominant-negative protein for the production and infectivity of HIV suggests that Nef plays an active role at this stage of the viral replicative cycle.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.